期刊
MOLECULAR PHARMACEUTICS
卷 6, 期 5, 页码 1353-1362出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp900021q
关键词
Multidrug-resistance (MDR); pH-sensitive micelle; endosomal pH targeting; folate receptor targeting; ovarian cancer
资金
- NCI NIH HHS [R01 CA101850-01A1, R01 CA101850-05A1, R01 CA101850, CA 101850] Funding Source: Medline
The second generation of pH-sensitive micelles composed of poly(L-histidine-co-L-phenlyalanine(16 mol %))(MW:5K)-b-PEG(MW:2K) and poly(L-lactic acid)(MW:3K)-b-PEG(MW:2K)-folate (80/20 wt/wt %) was previously optimized by physicochemical and in vitro tests for both folate receptor and early endosomal pH targeting (pH similar to 6.0). In this study, the therapeutic efficacy of the doxorubicin (DOX)-loaded micelles (DOX loading content: 20 wt %) was evaluated using in vivo tests. Multidrug-resistant (MDR) ovarian tumor-xenografted mouse models were employed. The skin-fold dorsal window chamber model was applied for visualization of extravasation and drug retention for the initial one hour after iv injection. Noninvasive imaging followed, providing evidence of drug accumulation in the tumor after the first hour. The biodistribution study further supported the long circulation of the drug carrier, tumor-selective accumulation and intracellular drug delivery. Comprehensive tumor growth inhibition experiments examined the collective efficacy of the pH-sensitive micelles. The micelle formulation effectively suppressed the growth of existing MDR tumors in mice for at least 50 days by three iv injections at a 3-day interval at a dose of 10 mg of DOX/kg. The body weight of the animals treated with the test micelle formulation gradually increased over the experimental time period, rather than decreasing. The micelle formulation was superior to its first generation, which targeted pH 6.8 and folate receptor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据